Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Exidavnemab phase 2a study expanded to include MSA patients

Contributed by: PR Newswire

Tags

BIOARCTIC-Exidavnemab

More Like This

BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review

First patient dosed in EXIST Phase 2a study in Parkinson's disease

BioArctic receives Orphan Drug Designation for exidavnemab the US

Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us